PE20151327A1 - Heterociclos n-acetilados y de nitrogeno saturados que potencian la actividad de un antibiotico activo contra micobacterias - Google Patents

Heterociclos n-acetilados y de nitrogeno saturados que potencian la actividad de un antibiotico activo contra micobacterias

Info

Publication number
PE20151327A1
PE20151327A1 PE2015001024A PE2015001024A PE20151327A1 PE 20151327 A1 PE20151327 A1 PE 20151327A1 PE 2015001024 A PE2015001024 A PE 2015001024A PE 2015001024 A PE2015001024 A PE 2015001024A PE 20151327 A1 PE20151327 A1 PE 20151327A1
Authority
PE
Peru
Prior art keywords
activity
active against
acetylated
enhance
antibiotic
Prior art date
Application number
PE2015001024A
Other languages
English (en)
Spanish (es)
Inventor
Nicolas Willand
Benoit Deprez
Alain Baulard
Priscille Brodin
Marion Flipo
Lucie Maingot
Original Assignee
Univ Lille Ii Droit & Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lille Ii Droit & Sante filed Critical Univ Lille Ii Droit & Sante
Publication of PE20151327A1 publication Critical patent/PE20151327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
PE2015001024A 2012-12-21 2013-12-20 Heterociclos n-acetilados y de nitrogeno saturados que potencian la actividad de un antibiotico activo contra micobacterias PE20151327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1203548A FR3000065A1 (fr) 2012-12-21 2012-12-21 Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes

Publications (1)

Publication Number Publication Date
PE20151327A1 true PE20151327A1 (es) 2015-10-12

Family

ID=48521019

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001024A PE20151327A1 (es) 2012-12-21 2013-12-20 Heterociclos n-acetilados y de nitrogeno saturados que potencian la actividad de un antibiotico activo contra micobacterias

Country Status (23)

Country Link
US (1) US9957249B2 (enExample)
EP (1) EP2935212B1 (enExample)
JP (1) JP6515035B2 (enExample)
KR (1) KR20150138152A (enExample)
CN (1) CN104955804B (enExample)
AU (1) AU2013366503B2 (enExample)
BR (1) BR112015014279A2 (enExample)
CA (1) CA2895606A1 (enExample)
CL (1) CL2015001640A1 (enExample)
CR (1) CR20150319A (enExample)
EA (1) EA028076B1 (enExample)
FR (1) FR3000065A1 (enExample)
GE (2) GEAP201813844A (enExample)
IL (1) IL239504B (enExample)
MA (1) MA38275B1 (enExample)
MX (1) MX2015008029A (enExample)
PE (1) PE20151327A1 (enExample)
PH (1) PH12015501427A1 (enExample)
SG (1) SG11201504492UA (enExample)
TN (1) TN2015000202A1 (enExample)
UA (1) UA117922C2 (enExample)
WO (1) WO2014096378A1 (enExample)
ZA (1) ZA201503719B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
DK3668853T3 (da) * 2017-08-16 2021-12-06 Glaxosmithkline Ip Dev Ltd Nye forbindelser
US11253499B2 (en) 2017-08-16 2022-02-22 Glaxosmithkline Intellectual Property Development Limited Compounds
ES2899365T3 (es) * 2017-08-16 2022-03-11 Glaxosmithkline Ip Dev Ltd Compuestos novedosos
RU2767542C1 (ru) * 2021-05-24 2022-03-17 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов
CN117903039A (zh) * 2023-12-26 2024-04-19 苏州艾缇克药物化学有限公司 一种1-Boc-4-(2-羧基苯基)哌啶的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
EP1118612A1 (en) * 2000-01-21 2001-07-25 Universita Degli Studi di Firenze Piperazine derivatives possesing nootropic activity
TW593556B (en) * 2002-12-27 2004-06-21 Ind Tech Res Inst Dichroic dye, composition thereof, and liquid crystal composition and liquid-crystal display element containing the same
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
FR2903405B1 (fr) * 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
TW200938203A (en) * 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
WO2009080432A2 (en) 2007-12-21 2009-07-02 Eth Zurich Composition for treatment of tuberculosis
US20110118262A1 (en) 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
WO2010044885A2 (en) * 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
FR2939135B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
US8912329B2 (en) 2009-06-25 2014-12-16 BioVersys AG Composition for treatment of tuberculosis
KR101179508B1 (ko) * 2010-06-24 2012-09-07 한국과학기술연구원 1,6-이치환-3-아미노-4,5,6,7-테트라하이드로-1Ｈ-피라졸로［3,4-ｃ］피리딘-7-온 화합물 및 이 화합물의 제조방법
WO2013060744A2 (en) 2011-10-25 2013-05-02 Universite De Droit Et De La Sante De Lille 2 Compounds having an ethr inhibiting activity - use of said compounds as drugs - pharmaceutical composition and product containing said compounds
EP2852585A1 (en) * 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
PL2875003T3 (pl) 2012-07-20 2017-05-31 Bayer Pharma Aktiengesellschaft Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes

Also Published As

Publication number Publication date
MA38275A1 (fr) 2017-11-30
EA201590828A1 (ru) 2015-11-30
IL239504A0 (en) 2015-08-31
SG11201504492UA (en) 2015-07-30
US9957249B2 (en) 2018-05-01
BR112015014279A2 (pt) 2017-07-11
PH12015501427B1 (en) 2015-09-14
EP2935212B1 (fr) 2019-02-27
AU2013366503B2 (en) 2018-02-01
US20150307471A1 (en) 2015-10-29
HK1215254A1 (zh) 2016-08-19
CR20150319A (es) 2015-09-14
WO2014096378A1 (fr) 2014-06-26
MA38275B1 (fr) 2018-09-28
PH12015501427A1 (en) 2015-09-14
EA028076B1 (ru) 2017-10-31
JP6515035B2 (ja) 2019-05-15
CN104955804A (zh) 2015-09-30
JP2016503778A (ja) 2016-02-08
CL2015001640A1 (es) 2016-01-29
EP2935212A1 (fr) 2015-10-28
ZA201503719B (en) 2016-11-30
FR3000065A1 (fr) 2014-06-27
GEP20186857B (en) 2018-06-11
MX2015008029A (es) 2015-10-30
IL239504B (en) 2018-10-31
GEAP201813844A (en) 2018-02-12
UA117922C2 (uk) 2018-10-25
CN104955804B (zh) 2018-02-09
KR20150138152A (ko) 2015-12-09
AU2013366503A1 (en) 2015-07-09
CA2895606A1 (fr) 2014-06-26
TN2015000202A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
MX2015008029A (es) Heterociclos n-acetilados y de nitrogeno saturados que potencian la actividad de un antibiotico activo contra micobacterias.
CU20160131A7 (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
DOP2017000310A (es) Inhibidores de metalo-beta-lactamasa
MX394441B (es) Una formulación a base de besifloxacina para usarse en el tratamiento del acné resistente a fármacos
CO2017005870A2 (es) Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
IL231358A (en) Topical veterinary compositions comprising an isoxazoline active agent for treating or preventing parasitic infection or infestation
BR112015013123A2 (pt) inibidores de beta-lactamase
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
MY176680A (en) Cyclic amides as metap-2 inhibitors
GT201300277A (es) Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardineria.
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
ITFI20110166A1 (it) Nuovi fotosensibilizzanti ad uso terapeutico.
PE20160801A1 (es) Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos
MX385774B (es) Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
ECSP15003613A (es) Formulación transdérmica que contiene inhibidores de cox
EA201590876A1 (ru) Спироизоксазолиновые соединения, обладающие активностью, усиливающей активность антибиотика
CL2021003592A1 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos.
EA201690963A1 (ru) КРИСТАЛЛИЧЕСКИЙ ИНГИБИТОР β-ЛАКТАМАЗЫ
TH161861A (enExample)
CR20160412A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas